logo
US overdose deaths fell 27% last year but remain above prepandemic levels

US overdose deaths fell 27% last year but remain above prepandemic levels

There were 30,000 fewer U.S. drug overdose deaths in 2024 than the year before — the largest one-year decline ever recorded.
An estimated 80,000 people died from overdoses last year, according to provisional Centers for Disease Control and Prevention data released Wednesday. That's down 27% from the 110,000 in 2023.
The CDC has been collecting comparable data for 45 years. The previous largest one-year drop was 4% in 2018, according to the agency's National Center for Health Statistics.
All but two states saw declines last year — with some of the biggest in Ohio, West Virginia and other states that have been hard-hit in the nation's decades-long overdose epidemic.
Experts say more research needs to be done to understand what drove the reduction, but they mention several possible factors. Among the most cited:
— Increased availability of the overdose-reversing drug naloxone.
— Expanded addiction treatment.
— Shifts in how people use drugs.
— The growing impact of billions of dollars in opioid lawsuit settlement money.
— The number of at-risk Americans is shrinking, after waves of deaths in older adults and a shift in teens and younger adults away from the drugs that cause most deaths.
Still, annual overdose deaths are higher than they were before the COVID-19 pandemic. And some experts worry that the recent decline could be slowed or stopped by reductions in federal funding and the public health workforce, or a shift away from the strategies that seem to be working.
'Now is not the time to take the foot off the gas pedal,' said Dr. Daniel Ciccarone, a drug policy expert at the University of California, San Francisco.
The provisional numbers are estimates of everyone who died of overdoses in the U.S., including noncitizens. That data is still being processed, and the final numbers can sometimes differ a bit. But it's clear that there was a huge drop last year.
Experts note that there have been past moments when U.S. overdose deaths seemed to have plateaued or even started to go down, only to rise again. That happened in 2018.
But there are reasons to be optimistic.
Naloxone has become more widely available, in part because of the introduction of over-the-counter versions that don't require prescriptions.
Meanwhile, drug manufacturers, distributors, pharmacy chains and other businesses have settled lawsuits with state and local governments over the painkillers that were a main driver of overdose deaths in the past. The deals over the last decade or so have promised about $50 billion over time, with most of it required to be used to fight addiction.
Another settlement that would be among the largest, with members of the Sackler family who own OxyContin maker Purdue Pharma agreeing to pay up to $7 billion, could be approved this year.
The money, along with federal taxpayer funding, is going to a variety of programs, including supportive housing and harm reduction efforts, such as providing materials to test drugs for fentanyl, the biggest driver of overdoses now.
But what each state will do with that money is currently at issue. 'States can either say, 'We won, we can walk away'' in the wake of the declines or they can use the lawsuit money on naloxone and other efforts, said Regina LaBelle, a former acting director of the Office of National Drug Control Policy. She now heads an addiction and public policy program at Georgetown University.
President Donald Trump's administration views opioids as largely a law enforcement issue and as a reason to step up border security. That worries many public health leaders and advocates.
'We believe that taking a public health approach that seeks to support — not punish — people who use drugs is crucial to ending the overdose crisis,' said Dr. Tamara Olt, an Illinois woman whose 16-year-old son died of a heroin overdose in 2012. She is now executive director of Broken No Moore, an advocacy organization focused on substance use disorder.
Olt attributes recent declines to the growing availability of naloxone, work to make treatment available, and wider awareness of the problem.
Kimberly Douglas, an Illinois whose 17-year-old son died of an overdose in 2023, credited the growing chorus of grieving mothers. 'Eventually people are going to start listening. Unfortunately, it's taken 10-plus years.'
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Denver Fork Cancer event to fight cancer, raise awareness for patients one bite at a time
Denver Fork Cancer event to fight cancer, raise awareness for patients one bite at a time

CBS News

timean hour ago

  • CBS News

Denver Fork Cancer event to fight cancer, raise awareness for patients one bite at a time

Fundraiser called Fork Cancer to take place in July in Denver Fundraiser called Fork Cancer to take place in July in Denver Fundraiser called Fork Cancer to take place in July in Denver In Colorado, about one-in-two men and two-in-five women will be diagnosed with some form of cancer in their lifetimes. It's a common disease in our state, with about 25,000 Coloradans diagnosed every year. American Cancer Society Cancer Action Network But Fork Cancer, hosted by the American Cancer Society Cancer Action Network, is helping fight cancer. American Cancer Society Cancer Action Network The party with a purpose features Denver fine culinary establishments while offering a variety of small plates, spirits and brews, and live entertainment acts. Ocular melanoma survivor Katie Doble will also share her powerful story of resilience. American Cancer Society Cancer Action Network You're invited to Fork Cancer, July 17th at 6:30pm at Mile High Station. CBS Colorado Anchor Mekialaya White will host the event. Tickets are available here.

Lead concerns in Milwaukee Public Schools; new push for federal help
Lead concerns in Milwaukee Public Schools; new push for federal help

Yahoo

time2 hours ago

  • Yahoo

Lead concerns in Milwaukee Public Schools; new push for federal help

The Brief Wisconsin Sen. Tammy Baldwin is making a new push for federal help to address the lead concerns in Milwaukee Public Schools. Six MPS schools have been shut down in 2025 because of the lead concerns. Four remain closed. MILWAUKEE - Dangerous lead levels forced the closures of six Milwaukee Public Schools in 2025. Four of those six remain shut down. Now, there is a new push for federal help on the matter. What we know Westside Academy is one of six Milwaukee Public Schools shut down for dangerous lead levels. Koa Branch has two children who attend school there. Even before the lead problem at Westside, Branch regularly had her kids tested for lead. Moving schools was a test for her kindergartner, Jonas. What they're saying "We're getting them tested again, tonight. I'm just nervous about it, so I just test them whenever I feel I need to test them," Branch said. Other MPS parents shared similar problems during a roundtable with U.S. Senator Tammy Baldwin (D-Wisconsin) on Monday, June 9. FREE DOWNLOAD: Get breaking news alerts in the FOX LOCAL Mobile app for iOS or Android "I run a tight schedule. So, I'm used to my son getting off the bus at 2:36, so I can be at work by three, so now I'm getting late to work. I mean the communication with Brown Street is excellent, the transition, as far as getting them to school is excellent. But, it just took us out of our routine," said Santana Wells, a parent of a Brown Street School student. What we know Sen. Baldwin is now inviting U.S. Health and Human Services Secretary Robert Kennedy to visit Milwaukee and hear the stories from parents like Branch and Wells. "These children are people. It is not a blue or a red issue. This is everybody's issue," said Shyquetta McElroy, Coalition on Lead Emergency. SIGN UP TODAY: Get daily headlines, breaking news emails from FOX6 News The senator urges the Trump administration to reinstate laid off CDC lead experts. "They could make the situation better today, by rehiring these experts," Baldwin said. Dig deeper In April, the CDC told the Milwaukee Health Department it could not send a team of lead experts. The CDC blamed it on the complete loss of the lead program. Secretary Kennedy told reporters in April, he thought that the program was being reinstated. But Sen. Baldwin said she is still waiting. "He either was lying or he didn't know what was happening in his own department. And I don't know which is worse," Baldwin said. HHS said the CDC did help validate new lab equipment for Milwaukee's lead testing. A Milwaukee Health Department spokeswoman said that was a single lab tech who helped calibrate a new machine, not the team of experts once in discussions to come to Milwaukee. The Source The information in this post was produced by FOX6 News.

Part D Cancer Drug Launch Prices Soar Past Inflation
Part D Cancer Drug Launch Prices Soar Past Inflation

Medscape

time2 hours ago

  • Medscape

Part D Cancer Drug Launch Prices Soar Past Inflation

Launch prices for Medicare Part D anticancer drugs have risen sharply since 2012, with a mean increase of $1694 per year. In 2025, the observed prices were 15%-200% higher than expected if the increases were due to inflation alone, but the gap between observed and inflation-adjusted prices narrowed over the study period. METHODOLOGY: The Inflation Reduction Act of 2022 introduced price negotiation for Medicare-covered drugs and required manufacturers to pay rebates to Medicare for price increases above inflation. But it did not address the launch prices of new drugs. Anticancer drugs, a protected drug class with mandatory Medicare Part D coverage, may now be especially prone to higher launch prices, in part because the Inflation Reduction Act limits out-of-pocket spending and price increases after market entry. Researchers identified 86 branded, self-administered, molecularly targeted anticancer therapies approved by the FDA between January 2010 and December 2024. Data on drug prices were obtained from the Medicare Prescription Drug Plan Formulary and adjusted for inflation. The researchers looked at launch prices by year and compared drug prices in 2025 with those expected if launch prices had increased due to inflation alone since the drug's market entry. TAKEAWAY: The mean monthly launch price increased from $10,954 for drugs first observed in the Medicare formulary in 2012-2014 to $27,891 for drugs first observed in 2023-2025. After adjusting for inflation, the mean launch price increased by $1694 per year ( P < .001). < .001). In 2025, actual drug prices were 14.8%-200.9% higher than expected if they had only kept pace with inflation. Although the gap between observed and inflation-adjusted prices narrowed over time, price increases continued to outpace inflation in 2023 and 2024, despite the Inflation Reduction Act rebate requirement, which will result in rebates to Medicare starting in fall 2025. IN PRACTICE: 'Launch prices for self-administered targeted anticancer therapies have grown precipitously, although no evidence was found of disproportionate increases in recent years. Instead, continued launch price growth for anticancer therapies was observed, consistent with prior research,' the study authors wrote. 'This suggests that companies were already engaging in price maximization for anticancer therapies and continued to do so after the implementation of the [Inflation Reduction Act].' SOURCE: This study, led by Stacie B. Dusetzina, PhD, Vanderbilt University School of Medicine in Nashville, Tennessee, was published online in JAMA . LIMITATIONS: This study used example indications to determine monthly doses and pricing. Additionally, variations in available price measures were noted over the study period. DISCLOSURES: This study was funded by Arnold Ventures. Several authors reported receiving grants or personal fees and having other ties with various sources.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store